RxSight, Inc. (RXST)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$4.99+8.71%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · RXST
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -54.0% |
| Our one-year growth estimate | diamond | 3.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 57.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 28 industry peers · Company calendar date is not available
RXST — CEO transition
Dated 2026-07-15
President and Chief Executive Officer — Aziz Mottiwala: Aziz Mottiwala was appointed as President and Chief Executive Officer, replacing Ron Kurtz, M.D.
Why it matters: RxSight withdrew its 2026 guidance during the CEO change. A clear plan can show how the company will address weak sales.
Watch forThe company gives a clear plan to raise sales, with steps and a date for formal guidance in early 2027.
Also watch forThe company gives no clear steps for its operations, or delays formal guidance past early 2027.
Why it matters: Q2 product sales fell 19% year over year. A smaller drop would show that sales pressure is easing.
Watch forQ3 product sales exceed $27.2 million, the Q2 2026 level, and rise year over year.
Also watch forQ3 product sales fall below $27.2 million and decline more than 19% year over year.
Why it matters: The new LAL, LAL+ and LAL Toric lenses aim to improve care and cut office visits. A firm launch date would show progress beyond development.
Supportive ifRxSight names a launch date for at least one new lens and reports that required follow-up visits are lower.
Worry ifRxSight delays the planned launches or shows no progress toward fewer follow-up visits.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$251 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $626 loss on $10,000 · 6.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,555 loss on $10,000 · 65.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.